Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06813820 · ClinicalTrials.gov registry record · NA
RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial
A NA study of CHF and Left Ventricle Remodeling, sponsored by BioVentrix.
- Recruiting
- Registry status
- NA
- Development phase
- 135
- Enrollment target
- 6
- Study locations
NCT06813820 is a NA study of CHF and Left Ventricle Remodeling that is actively recruiting participants, run by BioVentrix. The registered enrollment target is 135 participants, below the 172-participant average among 5 other CHF trials with a reported enrollment target (22% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT06813820, a NA study of CHF and Left Ventricle Remodeling, is actively recruiting participants, sponsored by BioVentrix.
- RECRUITING
- Registry status
- NA
- Development phase
- 135 participants
- Enrollment target
- 6
- Study locations
Study Summary
A prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with approximately 128 evaluable patients and assuming 5% loss to follow-up. A primary safety endpoint will be evaluated at 30 days. Primary efficacy endpoint will be at 1 year. Interim efficacy endpoints will be evaluated at 6 months.
Conditions Studied
Interventions
- DEVICE Revivent System
Study Locations (6)
Arizona
- Banner University Medical Center - Phoenix
Florida
- Baptist Health South Florida - Miami
Illinois
- University of Chicago - Chicago
Missouri
- Saint Luke's Hospital of Kansas City - Kansas City
Oklahoma
- Oklahoma Heart Hospital - Oklahoma City
Pennsylvania
- Penn State Health - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2032-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06813820
The ClinicalTrials.gov registry entry for NCT06813820 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 5 other CHF trials with a reported enrollment target (22% lower). The listed sponsor is BioVentrix, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with CHF appearing as the primary indexed condition, and to 1 intervention - of which Revivent System is the first listed.
NCT06813820 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06813820 about?
NCT06813820 is a clinical study titled "RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial". A prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with approximately 128 evaluable patients and assuming 5% loss to follow-up. A primary...
What is the current status of trial NCT06813820?
This trial is currently recruiting. It is a NA study. The enrollment target is 135 participants. The study started on 2025-09-29. Estimated completion is 2032-08.
What conditions does trial NCT06813820 study?
This clinical trial studies the following conditions: CHF, Left Ventricle Remodeling, Left Ventricle Dilated.
What interventions are being tested in trial NCT06813820?
The interventions under investigation include: Revivent System (DEVICE).
Who is sponsoring clinical trial NCT06813820?
This trial is sponsored by BioVentrix, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06813820 being conducted?
This trial has 6 study locations across Arizona, Florida, Illinois, Missouri, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CHF
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD
COMPLETED · NA
-
Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)
RECRUITING
-
Biomarkers for Human Heart Failure
COMPLETED
-
PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients
COMPLETED · Phase 1
-
Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.